BofA Securities stays Buy on Ionis Pharmaceuticals (IONS) as new pricing 'a positive update'

March 25, 2026 12:24 PM

BofA Securities analyst Jason Gerberry reiterated a Buy rating and $100.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found